Tirzepatide pen 20 mg (GLP1+GIP)

Satus:

Available

Shipping:

1-3 business days DHL, FedEx

Chemical reagent

Tirzepatide 20 mg pen is an advanced synthetic peptide with dual activity against GLP-1R and GIPR receptors, which is the subject of intensive research on metabolic regulation, energy balance control and body weight.

299.00 €

-10%

for a second product

-20%

for the fourth product

European Shipping

1-3 business days

Warranty
quality

Reviewed
products

Tirzepatide 20 mg pen - an advanced agonist for metabolic studies

What is Tirzepatide 20 mg pen?

Tirzepatide 20 mg pen is a synthetic peptide analog designed as a dual agonist of GLP-1R and GIPR receptors. The design of the molecule allows simultaneous activation of two key incretin pathways, making it a tirzepatide 20 mg pen an interesting research model in analyses of energy regulation and integration of hormonal signaling.

Type form pen reflects the dosing model used in clinical trials and allows analysis of pharmacokinetic parameters and dose-response relationships under controlled laboratory conditions. In the research context tirzepatide 20 mg pen represents a variant to assess higher receptor exposure.

Mechanism of receptor action

Tirzepatide 20 mg pen works by simultaneously activating receptors:

GLP-1R - associated with modulation of cAMP signaling and insulinotropic responses,
GIPR - involved in the regulation of glucose metabolism and the integration of incretin signaling.

Dual receptor activation leads to an integrated metabolic response, including modulation of the glucose-insulin axis and effects on mechanisms regulating energy balance.

Mechanistic reviews have shown that simultaneous activation of GIP and GLP-1 can generate a synergistic effect by potentiating cAMP-dependent signaling and activating Gs protein. Molecular studies observed a pronounced dose-dependent effect and intensification of GPCR signaling with increased exposure, making the tirzepatide 20 mg pen a useful tool in pharmacodynamic analyses.

Relevance in clinical and preclinical studies

The SURPASS and SURMOUNT study programs analyzed the effects of tirzepatydu on metabolic parameters at long-term follow-up. In the SURMOUNT-1 study (72 weeks), a mean weight reduction of 20.9% and a clear dose-response relationship were reported for the highest doses analyzed.

SURPASS-2 showed greater reductions in HbA1c compared to a selective GLP-1 agonist, confirming the importance of dual receptor agonism.

In preclinical studies, dual GIP/GLP-1 agonism has been analyzed as a model of receptor synergy to study the integration of cAMP pathways and their effects on lipid and carbohydrate metabolism. In this context tirzepatide 20 mg pen provides a variant to assess the intensification of the receptor response.

Tirzepatide 20 mg pen versus other incretin agonists

In receptor terms:

Semaglutide only activates GLP-1R,
tirzepatide (including tirzepatide 20 mg pen) activates GLP-1R and GIPR,
retatrutide additionally involves the glucagon receptor (GCGR).

The range of activated receptors determines the complexity of the metabolic response and is a key element in differentiating molecules in pharmacodynamic analyses.

Sources:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10159347

https://pubmed.ncbi.nlm.nih.gov/23850282/

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.

Laboratory tests to confirm the quality and authenticity of products

INTENDED FOR RESEARCH PURPOSES!
All properties mentioned above are observed with laboratory tests, not done on humans, and are for informational purposes only. Any information contained in the descriptions has not been approved by GIS, GIF or EFSA. The substance is not a drug, food product or dietary supplement, consequently it is not suitable for human consumption. The product qualifies as a chemical reagent / reference material approved for marketing in the EU. It can only be used for scientific research. For other information on the agent, please refer to the Material Safety Data Sheet, which is available for review. The products are available only to institutions or individuals who are associated with research or laboratory activities.